Literature DB >> 28228413

Determination of Human Hepatic CYP2C8 and CYP1A2 Age-Dependent Expression to Support Human Health Risk Assessment for Early Ages.

Gina Song1, Xueying Sun1, Ronald N Hines1, D Gail McCarver1, Brian G Lake1, Thomas G Osimitz1, Moire R Creek1, Harvey J Clewell1, Miyoung Yoon2.   

Abstract

Predicting age-specific metabolism is important for evaluating age-related drug and chemical sensitivity. Multiple cytochrome P450s and carboxylesterase enzymes are responsible for human pyrethroid metabolism. Complete ontogeny data for each enzyme are needed to support in vitro to in vivo extrapolation (IVIVE). This study was designed to determine age-dependent human hepatic CYP2C8 expression, for which only limited ontogeny data are available, and to further define CYP1A2 ontogeny. CYP2C8 and 1A2 protein levels were measured by quantitative Western blotting using liver microsomal samples prepared from 222 subjects with ages ranging from 8 weeks gestation to 18 years after birth. The median CYP2C8 expression was significantly greater among samples from subjects older than 35 postnatal days (n = 122) compared with fetal samples and those from very young infants (fetal to 35 days postnatal, n = 100) (0.00 vs. 13.38 pmol/mg microsomal protein; p < 0.0001). In contrast, the median CYP1A2 expression was significantly greater after 15 months postnatal age (n = 55) than in fetal and younger postnatal samples (fetal to 15 months postnatal, n = 167) (0.0167 vs. 2.354 pmol/mg microsomal protein; p < 0.0001). CYP2C8, but not CYP1A2, protein levels significantly correlated with those of CYP2C9, CYP2C19, and CYP3A4 (p < 0.001), consistent with CYP2C8 and CYP1A2 ontogeny probably being controlled by different mechanisms. This study provides key data for the physiologically based pharmacokinetic model-based prediction of age-dependent pyrethroid metabolism, which will be used for IVIVE to support pyrethroid risk assessment for early life stages. U.S. Government work not protected by U.S. copyright.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28228413     DOI: 10.1124/dmd.116.074583

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  11 in total

1.  Biocomparison Study of Adult and Paediatric Dose Strengths of the Prostacyclin Receptor Agonist Selexipag.

Authors:  Margaux Boehler; Shirin Bruderer; Ivan Ulč; Jasper Dingemanse
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-02       Impact factor: 2.441

2.  A Time-Embedding Network Models the Ontogeny of 23 Hepatic Drug Metabolizing Enzymes.

Authors:  Matthew K Matlock; Abhik Tambe; Jack Elliott-Higgins; Ronald N Hines; Grover P Miller; S Joshua Swamidass
Journal:  Chem Res Toxicol       Date:  2019-07-29       Impact factor: 3.739

Review 3.  [Recent research on gene polymorphisms related to caffeine therapy in preterm infants with apnea of prematurity].

Authors:  Jiang-Biao Xie; Xin-Zhu Lin
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-07-15

4.  Physiologically-Based Pharmacokinetic Modeling to Investigate the Effect of Maturation on Buprenorphine Pharmacokinetics in Newborns with Neonatal Opioid Withdrawal Syndrome.

Authors:  Matthijs W van Hoogdalem; Trevor N Johnson; Brooks T McPhail; Suyog Kamatkar; Scott L Wexelblatt; Laura P Ward; Uwe Christians; Henry T Akinbi; Alexander A Vinks; Tomoyuki Mizuno
Journal:  Clin Pharmacol Ther       Date:  2021-11-21       Impact factor: 6.903

Review 5.  Developmental regulation of kidney and liver solute carrier and ATP-binding cassette drug transporters and drug metabolizing enzymes: the role of remote organ communication.

Authors:  Jeremiah D Momper; Sanjay K Nigam
Journal:  Expert Opin Drug Metab Toxicol       Date:  2018-06-04       Impact factor: 4.481

6.  Development and Application of a Life-Stage Physiologically Based Pharmacokinetic (PBPK) Model to the Assessment of Internal Dose of Pyrethroids in Humans.

Authors:  Pankajini Mallick; Marjory Moreau; Gina Song; Alina Y Efremenko; Salil N Pendse; Moire R Creek; Thomas G Osimitz; Ronald N Hines; Paul Hinderliter; Harvey J Clewell; Brian G Lake; Miyoung Yoon
Journal:  Toxicol Sci       Date:  2020-01-01       Impact factor: 4.849

7.  Pharmacokinetic profile of amodiaquine and its active metabolite desethylamodiaquine in Ghanaian patients with uncomplicated falciparum malaria.

Authors:  Thomas A Anyorigiya; Sandra Castel; Katya Mauff; Frank Atuguba; Bernhards Ogutu; Abraham Oduro; David Dosoo; Kwaku-Poku Asante; Seth Owusu-Agyei; Alexander Dodoo; Abraham Hodgson; Fred Binka; Lesley J Workman; Elizabeth N Allen; Paolo Denti; Lubbe Wiesner; Karen I Barnes
Journal:  Malar J       Date:  2021-01-06       Impact factor: 2.979

8.  Pharmacokinetic Evaluation of Eltrombopag in ITP Pediatric Patients.

Authors:  Marco Dionisi; Sara Cairoli; Raffaele Simeoli; Francesca De Gennaro; Valeria Paganelli; Roberto Carta; Francesca Rossi; Carlo Dionisi-Vici; Giuseppe Palumbo; Bianca Maria Goffredo
Journal:  Front Pharmacol       Date:  2021-12-06       Impact factor: 5.810

9.  Development of a physiologically based pharmacokinetic (PBPK) population model for Chinese elderly subjects.

Authors:  Cheng Cui; Jie En Valerie Sia; Siqi Tu; Xiaobei Li; Zhongqi Dong; Zhiheng Yu; Xueting Yao; Oliver Hatley; Haiyan Li; Dongyang Liu
Journal:  Br J Clin Pharmacol       Date:  2021-05-18       Impact factor: 4.335

Review 10.  Physiologically Based Pharmacokinetic Models Are Effective Support for Pediatric Drug Development.

Authors:  Kefei Wang; Kun Jiang; Xiaoyi Wei; Yulan Li; Tiejie Wang; Yang Song
Journal:  AAPS PharmSciTech       Date:  2021-07-26       Impact factor: 3.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.